The global Benign Prostatic Hyperplasia (BPH) surgical treatment market is experiencing substantial growth, driven by the increasing prevalence of BPH among aging males and the rising demand for effective surgical interventions. BPH, a non-cancerous enlargement of the prostate gland, leads to lower urinary tract symptoms (LUTS) that significantly impact the quality of life. Surgical treatments are often pursued when pharmacological therapies fail to provide adequate relief.

In 2024, the market was valued at approximately USD 12.62 billionand is projected to reach USD 21.19 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period.

Market Segmentation

The BPH surgical treatment market can be segmented based on procedure type, drug type, therapy, end-user, and region.

By Procedure Type:

• Transurethral Resection of the Prostate (TURP): Considered the gold standard, TURP involves the removal of prostate tissue to relieve obstruction. It is widely adopted due to its efficacy and established clinical outcomes.
• Laser Therapies: Techniques such as Holmium Laser Enucleation of the Prostate (HoLEP) and Photoselective Vaporization of the Prostate (PVP) offer minimally invasive alternatives with reduced bleeding and shorter hospital stays.
• Prostatic Urethral Lift (PUL): This procedure involves the placement of implants to retract prostate tissue, thereby opening the urethra without cutting or removing tissue.
• Water Vapor Thermal Therapy (Rezum): Utilizes steam to ablate prostate tissue, offering a minimally invasive option with preservation of sexual function.
• Prostatic Artery Embolization (PAE): A radiological procedure that reduces blood flow to the prostate, leading to shrinkage and symptom relief.

By Drug Type:

While surgical treatments are the focus, pharmacological therapies often precede surgical intervention. Key drug types include:

• Alpha-Blockers: Relax prostate and bladder neck muscles to improve urine flow.
• 5-Alpha Reductase Inhibitors: Reduce prostate size by inhibiting hormonal changes.

By Therapy:

• Monotherapy: Use of a single drug type.
• Combination Therapy: Concurrent use of multiple drug types for enhanced efficacy.

By End-User:

• Hospitals: Primary centers for surgical interventions with comprehensive facilities.
• Ambulatory Surgical Centers (ASCs): Offer outpatient procedures with shorter recovery times.
• Clinics: Provide initial assessments and follow-up care.

Regional Analysis

North America:

North America holds the largest share of the BPH surgical treatment market, attributed to the high prevalence of BPH, advanced healthcare infrastructure, and the adoption of innovative surgical techniques. The region's focus on minimally invasive procedures has led to increased utilization of laser therapies and PUL.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 @ https://www.polarismarketresearch.com/industry-analysis/benign-prostatic-hyperplasia-surgical-treatment-market

Europe:

Europe follows closely, with countries like Germany, the UK, and France contributing significantly. The region benefits from a well-established healthcare system and a growing elderly population. Emphasis on patient-centric care and technological advancements support market growth.

Asia-Pacific:

The Asia-Pacific region is expected to witness the fastest growth during the forecast period. Factors such as increasing awareness, improving healthcare infrastructure, and a rising geriatric population drive demand. Countries like China, Japan, and India are investing in healthcare reforms, facilitating market expansion.

Latin America and Middle East & Africa:

These regions are gradually adopting advanced BPH surgical treatments. Economic development, urbanization, and healthcare investments contribute to market growth, albeit at a slower pace compared to other regions.

Key Companies

Several companies are actively contributing to the BPH surgical treatment market through innovation and strategic initiatives:

• Boston Scientific Corporation: Offers a range of minimally invasive therapies, including the GreenLight Laser Therapy system.
• Teleflex Incorporated: Known for the UroLift System, a minimally invasive treatment for BPH.
• Olympus Corporation: Provides endoscopic equipment and laser systems for urological procedures.
• PROCEPT BioRobotics Corporation: Developer of the AquaBeam Robotic System for waterjet ablation therapy.
• Coloplast Group: Offers urology products, including surgical solutions for BPH.
• Richard Wolf GmbH: Specializes in endoscopic instruments and systems for urological surgeries.
• Karl Storz SE & Co. KG: Provides a comprehensive range of endoscopic equipment for urology.
• Quanta System: Manufacturer of laser systems used in various surgical applications, including BPH treatment.
• IPG Photonics Corporation: Develops high-power fiber lasers utilized in medical procedures.
• ProstaLund AB: Focuses on thermal therapies for BPH treatment.

These companies are investing in research and development to enhance surgical outcomes, reduce recovery times, and improve patient satisfaction.

Conclusion

The global BPH surgical treatment market is poised for significant growth, driven by technological advancements, increasing prevalence of BPH, and a shift towards minimally invasive procedures. As the aging male population continues to rise, the demand for effective and patient-friendly surgical options will escalate. Stakeholders in the healthcare industry must focus on innovation, accessibility, and education to meet the evolving needs of patients and capitalize on emerging opportunities in this dynamic market.